Altimmune (ALT) Drops -31% Over 30 Days as Momentum Fades

Key Takeaways

• Altimmune (ALT) shares declined roughly 31% over the last 30 days, falling from about $2.96 to near $2.04.
• The pullback followed a strong run-up that pushed the stock to a multi-month high around $3.42 in early September.
• Over the last quarter, ALT has also lost approximately 30%, erasing gains tied to positive pemvidutide clinical data reported in July and August.
• No single company-specific negative event drove the slide; the decline reflects profit-taking and thinning near-term catalysts in a pre-revenue biotech.
• Fundamentals remain supported by a $519 million cash position and a pipeline advancing the Phase 3 PERFORMA trial in MASH.

Altimmune's Pipeline in Liver Disease

Altimmune is a late clinical-stage biopharmaceutical company focused on developing therapies for serious liver diseases. Its lead candidate, pemvidutide, is an investigational peptide designed as a balanced 1:1 glucagon/GLP-1 dual receptor agonist. The company is advancing pemvidutide across three indications: metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD), and alcohol-associated liver disease (ALD).

The U.S. Food and Drug Administration has granted pemvidutide Fast Track designation for both MASH and AUD, as well as Breakthrough Therapy designation for MASH. Investors follow ALT as a differentiated player in the fast-growing metabolic and liver disease space, a category that has attracted intense attention given the commercial success of GLP-1 therapies. Because the company has no marketed products, it does not generate revenue and remains dependent on its cash reserves and financing to fund development.

Recent Stock Performance: 30 Days and the Quarter

Over the last 30 days, ALT shares fell from approximately $2.96 to a latest close near $2.04, a decline of about 31%. The move was not a single-day gap but a steady, multi-week slide that accelerated in mid-October, with the stock reaching its recent low of the period. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.

The quarterly picture tells a similar but more nuanced story. ALT traded near $2.99 in late July, rallied to a multi-month high of about $3.42 in early September, and then reversed sharply to close near $2.04 in late October. On a quarter-over-quarter basis, the stock is down roughly 30%, meaning the September peak has been fully retraced and then some.

Factors Behind the Recent Decline

The last 30 days did not bring a major negative clinical readout or a single decisive catalyst for Altimmune. Instead, the decline appears to reflect a combination of profit-taking, a thinner slate of near-term catalysts, and broader pressure on small-cap biotechnology stocks.

After positive Phase 2 RECLAIM results in alcohol use disorder reported in late July and the announcement of the Phase 3 PERFORMA MASH trial initiation in August, the stock rallied into early September. With no new data events scheduled in the immediate weeks that followed, momentum faded and investors rotated out of a position that had already delivered a sizable run.

Additional factors likely weighed on sentiment. As a pre-revenue company, Altimmune is sensitive to interest-rate expectations and risk appetite, and small-cap biotech has faced sector-wide volatility. Financing overhang from earlier capital raises, including a $225 million public offering completed in April 2026, can also influence trading in the shares. In late October, the company announced new board appointments, part of a planned succession tied to its transition toward late-stage development.

Quarterly Moves and Clinical Milestones

Altimmune's quarterly performance was defined by a sharp rise followed by an equally sharp reversal. In late July, the company reported positive topline results from the RECLAIM Phase 2 trial of pemvidutide in alcohol use disorder, meeting its primary endpoint with a statistically significant reduction in heavy drinking days. In August, Altimmune initiated the global Phase 3 PERFORMA trial in MASH and completed patient enrollment in the Phase 2 RESTORE trial in alcohol-associated liver disease.

These milestones initially lifted the shares, but the absence of additional near-term readouts allowed sentiment to cool. Second-quarter results reported in August showed a narrower-than-expected net loss of $0.12 per share and a cash position of $519 million as of June 30, 2026, with management guiding a runway into 2029. While the balance sheet is strong, the long timelines to key data — ALD topline data in the second half of 2027 and MASH 52-week data anticipated in 2029 — mean the stock is now trading on a longer-horizon narrative rather than imminent catalysts.

Looking Ahead: Key Catalysts to Monitor

Looking ahead, several factors will shape Altimmune's trajectory. Investors should monitor upcoming quarterly earnings reports, including the third-quarter 2026 update, for updates on cash position, R&D spending, and pipeline progress. Regulatory discussions with the FDA on a path forward in alcohol use disorder following the RECLAIM data represent a key near-term event, as does continued enrollment and execution in the Phase 3 PERFORMA MASH trial.

Longer-term, the Phase 2 RESTORE trial in alcohol-associated liver disease is expected to report topline data in the second half of 2027, while 52-week data from PERFORMA is anticipated in 2029. Competitive developments in the MASH landscape, including from Madrigal Pharmaceuticals (MDGL), and broader GLP-1 category dynamics will also influence sentiment. As a pre-revenue biotech, Altimmune's shares will likely remain sensitive to financing decisions, sector rotation, and shifts in risk appetite.

Exploring AI Tools in My Research Process

In my own research, I often turn to Tickeron’s AI Trading Bots to see how automated strategies are tracking names like ALT. These tools provide a practical way to monitor patterns and signals across thousands of tickers without replacing core fundamental analysis.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Contributor

Sergey Savastiouk|Expert

Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.

Notable companies

Industry description

Market Cap

High and low price notable news

Volume